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Abstract
Background: A. oxyphylla extract is known to possess a wide range of pharmacological activites. However, the
molecular mechanism of A. oxyphylla and its bioactive compound nootkatone in colorectal cancer is unknown.
Methods: Our study aims to examine the role of A. oxyphylla and its bioactive compound nootkatone, in tumor
suppression using several in vitro assays.
Results: Both A. oxyphylla extract and nootkatone exhibited antiproliferative activity in colorectal cancer cells. A.
oxyphylla displayed antioxidant activity in colorectal cancer cells, likely mediated via induction of HO-1.
Furthermore, expression of pro-apoptotic protein NAG-1 and cell proliferative protein cyclin D1 were increased and
decreased respectively in the presence of A. oxyphylla. When examined for anticancer activity, nootkatone treatment
resulted in the reduction of colony and spheroid formation. Correspondingly, nootkatone also led to increased
NAG-1 expression and decreased cyclin D1 expression. The mechanism by which nootkatone suppresses cyclin D1
involves protein level regulation, whereas nootkatone increases NAG-1 expression at the transcriptional level. In
addition to having PPARγ binding activity, nootkatone also increases EGR-1 expression which ultimately results in
enhanced NAG-1 promoter activity.
Conclusion: In summary, our findings suggest that nootkatone is an anti-tumorigenic compound harboring
antiproliferative and pro-apoptotic activity.
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Background
Alpinia oxyphylla belongs to the Zingiberaceae family
and is widely cultivated in Asia as one of the most fre-
quently used plant extracts in oriental medicine. The
most well-known medicinal effect of A. oxyphylla in-
cludes enhancing the internal and astringent activities of
the kidney and spleen [1]. Recent studies have shown
that A. oxyphylla possesses a wide range of pharmaco-
logical activities, such as anti-diabetes [2], anti-fibrosis
[3], anti-diarrheal [4], and anti-cancer [5].
A. oxyphylla contains various chemical constituents,
including essential oils, sesquiterpenes, flavones, diaryl-
heptanoids, glycosides and steroids. Amongst them,
nootkatone is one of the more abundant components
[6]. Nootkatone has also been identified as the main fra-
grant component of grapefruit with a wide range of
beneficial effects including anti-inflammation activities
[7], AMPK activation [8] and neuroprotective effects [9].
Other bioactive compounds in A. oxyphylla,
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yakuchinone A [10] and yakuchinone B [11], are also
known to have several biological activities including
anti-cancer activity. However, the molecular target of
nootkatone and other bioactive compounds in cancer or
in cell proliferation is unknown.
By analyzing identified molecular targets of phyto-
chemicals, we discovered that the nonsteroidal anti-
inflammatory drug [NSAID]-activated gene-1 (NAG-1,
also known as GDF15) is highly induced by several phy-
tochemicals [12]. Ectopic expression of NAG-1 causes
cell growth arrest, and overexpression of NAG-1 in hu-
man colon cells results in reduced tumor formation in
the nude mouse model [13]. Although in vitro assays
show contradictory results, studies conducted in NAG-1
TG and NAG-1 KO mice consistently demonstrate a
clear association between NAG-1 expression and tumor
suppression [14]. Thus, NAG-1 induction is a likely mo-
lecular mechanism for anticancer activity induced by
phytochemicals.
Cyclin D1, another common target of phytochemicals,
is often overexpressed in various cancer cell types and
tumors. In addition to its role in the cell cycle, cyclin D1
functions as a critical regulator of DNA repair, and thus
constitutes a key molecular regulator of transcription
[15]. A large number of anticancer chemicals have been
shown to downregulate cyclin D1 in various cancer cell
types by triggering multiple signaling pathways [16].
EGR-1 is induced very early in the apoptotic process,
and mediates the activation of downstream regulators
such as p53 [17]. However, EGR-1-induced apoptosis
has also been reported in p53−/− cells, indicating the ex-
istence of both p53-dependent and p53-independent
pathways. EGR-1 also activates tumor suppressor gene
phosphatase and tensin homolog (PTEN) during UV ir-
radiation and suppresses the growth of transformed cells
both in soft agar and in athymic nude mice [18]. While
these results indicate that EGR-1 plays a significant role
in growth suppression, the consequences of EGR-1 ex-
pression may vary depending on the cellular context.
Discrepancies in its role may depend on expression
levels of other EGR-1 family members, Sp1, EGR-1 bind-
ing repressors, or other factors yet to be identified. Inter-
estingly, EGR-1 has been linked to increased NAG-1
promoter activity, mediated by nonsteroidal anti-
inflammatory drugs [19].
Thus, NAG-1, cyclin D1, or EGR-1 could be a mo-
lecular target of many bioactive compounds that
could lead to anti-proliferation activity. The identifica-
tion of the molecular target of nootkatone may lead
to the development of better single compounds for
cancer therapy.
In this study, we identified the biological activity of A.
oxyphylla and its major compound nootkatone as an in-
ducer of the pro-apoptotic protein NAG-1 and a
suppressor of cyclin D1, thereby inhibiting cell prolifera-
tion in colon cancer cells. Further, the mechanism by
which nootkatone affects cyclin D1 and NAG-1 has been
studied. Our results indicated that EGR-1 plays a pivotal
role in nootkatone-induced NAG-1 expression, while the
proteosomal degradation pathway contributes to
nootkatone-mediated cyclin D1 downregulation.
Methods
Reagents
A. oxyphylla was purchased from Kyung-Dong Market
in Seoul, Korea. The authenticity was confirmed at least
twice through morphological analysis by Dr. Jaeyoon Cha,
Department of Food Science and Nutrition, Dong-A Uni-
versity, Busan, Republic of Korea. A voucher specimen (No.
EHNP-H8) has been deposited in the R&D Center, EastHill
Corporation, Suwon, Gyeonggi-do, Republic of Korea. The
plants were washed and ground using a laboratory mill to a
particle size of 100 mesh. Ethanol (70%) was added to the
ground plants and extracted at 70 °C for 48 h with stirring
at 500 rpm. The extract was filtered using Toyo No. 4 filter
paper and concentrated using a vacuum evaporator. Finally,
the concentrate was diluted in dimethyl sulfoxide to obtain
a final concentration 100mg/mL. Nootkatone was pur-
chased from Tokyo Chemical Industry (Tokyo, Japan).
Epoxomicin and Puromycin (P8833–10) were purchased
from Sigma Aldrich (St. Louis, MO, USA) and MG132 was
purchased from AdooQ® Bioscience (Irvine, CA, USA).
Antibodies for Cyclin D1 (sc-753), HRP conjugated β-actin
(sc-47,778), and p53 (sc-126) were purchased from Santa
Cruz Biotechnology (Dallas, TX, USA). Antibody for NAG-
1 was previously described [13].
Cell culture
All cells used in this study were purchased from Ameri-
can Type Culture Collection (ATCC). Cells were tested
by ATCC for post-freeze viability, growth properties,
morphology, mycoplasma contamination, species deter-
mination (cytochrome c oxidase I assay and short tan-
dem repeat analysis), sterility test and human pathogenic
virus testing. Upon arrival, cell lines were straightaway
resuscitated and frozen in aliquots in liquid nitrogen.
HCT-116 (Human colorectal carcinoma) and HT-29
(Human colorectal adenocarcinoma) cells were cultured
using McCoy’s 5A media (Gibco life technologies, Carls-
bad, CA, USA). SW480 (Human colorectal adenocarcin-
oma), DLD-1 (Human colorectal adenocarcinoma) were
cultured using RPMI-1640 media (GIBCO). Both Mc-
Coy’s 5A media and RPMI-1640 media contained 10%
Fetal bovine serum (FBS; GIBCO) and 1% penicillin/
streptomycin (GIBCO). All cells were maintained at
37 °C and 5% CO2.
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Plasmid transfection and luciferase assay
The promoter-luciferase constructs pNAG1–1086/+ 41,
pNAG1–474/+ 41, and pNAG1–133/+ 41 were previ-
ously described [12]. The expression vector pcDNA-
EGR-1 has also been described [19]. The luciferase and
pRL-null plasmids were transfected into cells using Poly-
Jet™ In Vitro DNA Transfection reagent (SignaGen,
Frederick, MD, USA) according to manufacturer’s in-
structions. Luciferase activity was measured using Dual-
Luciferase® Reporter Assay kit (Promega, WI, USA) as
previously described [20].
Colony formation assay
Both HCT-116 and SW480 cells were seeded at a dens-
ity of 1 × 104 cells/well in 6-well culture plates. Cells
were treated with nootkatone at various doses (10 μM,
50 μM, or 100 μM) for 9 days. The culture media con-
taining indicated concentrations of nootkatone were
changed every 3 days. After treatment, the plate was
washed with phosphate-buffered saline, and cells were
fixed with 4% paraformaldehyde (Biosesang, Gyeonggi-
do, Korea), followed by staining with 1% crystal violet
solution (V5265, Sigma Aldrich). The number of
colonies was counted using Image J software 1.52a (Na-
tional Institutes of Health, MD, USA).
Western blot analysis
Western blot analysis was conducted as previously de-
scribed [21]. Briefly, 50 μg proteins were separated using
12% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and transferred to a nitrocellulose membrane
(GVS filter technology, Zola Predosa BO, Italy). The
blotted membrane was then blocked with 5% skim milk
for 1 hr at room temperature and incubated overnight
with specific antibodies at 4 °C. After incubation with
HRP conjugated secondary antibody in 5% skim milk for
1 hr at room temperature, the blotted membranes were
visualized using the Alliance Q9 mini imaging system
(Cambridge, UK) and quantified using ImageJ software
1.52a (National Institutes of Health, MD, USA).
RNA isolation and reverse transcription polymerase chain
reaction (RT-PCR)
Total RNA was isolated using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA). Five hundred nanograms of
total RNA was used to synthesize cDNA using Verso
cDNA Synthesis kit (Thermo scientific, Waltham, MA,
USA). PCR products were amplified using the following
primer pairs: cyclin D1 (F: 5′-CAA TGA CCC CGC
ACG ATT TC-3′, R: 5′-AAG TTG TTG GGG CTC
CTC AG-3′), NAG-1 (F: 5′-CTC CAG ATT CCG AGA
CTT GC-3′, R:5′-AGA CAT ACG CAG GTG CAG
GT-3′), GAPDH (F: 5′-GAC CAC AGT CCA TGC
CAT CAC T-3′, R: TCC ACC ACC CTG TTG CTG
TAG-3′). Thermal cycling conditions for NAG-1 were
as follows: initial denaturation at 95 °C for 2 min,
followed by 25–35 cycles of 94 °C for 30 s, 53.2 °C for 30
s, and 72 °C for 1 min, and final elongation at 72 °C for
5 min. For cyclin D1 and GAPDH, amplification and an-
nealing temperatures were set to 52.5 °C and 60 °C re-
spectively. PCR products were electrophoresed on a
1.5% agarose gel and photographed using the Alliance
Q9 mini imaging system.
Cell proliferation assay
HCT-116 and SW480 were seeded in 96-well plates (1 ×
103 cells/well for HCT-116 cells and 2 × 103 cells/well
for SW480 cells) and incubated for 24 h with 100 μL of
complete medium. Different dose of A. oxyphylla was
treated for the indicated time. Cell proliferation assays
were then performed using CellTiter 96® AQueous One
Solution (Promega, WI, USA) according to the manufac-
turer’s instructions. After indicated time of culture,
20 μL of One Solution reagent was added to each well
and cells were incubated for 1 h at 37 °C. Cell viability
was estimated by measuring the absorbance at 492 nm
using Multiskan FC spectrophotometer (Thermo Fisher
Scientific, Waltham, MA).
Antioxidant activity assay
The 2,2-diphenyl-1-picrylhydrazyl (DPPH, #14805, Cay-
man Chemical, MI, USA) and 2,2 -azino-bis(3-ethylben-
zothiazoline-6-sulfonic acid) (ABTS, #A1888, Sigma
Aldrich) were used for the radical scavenging assay, as
previously described [22]. The absorbance was measured
using a Multiskan™ FC microplate photometer (Thermo
Fisher Scientific, Waltham, MA). L-ascorbic acid
(#A0537, TCI, Tokyo, Japan) was used as a reference
standard in both assays. Determination of the percentage
of radical scavenging effect was considered using the fol-
lowing equation:
%Inhibition ¼ 100 − ½ Absorbance of sample −Absorbance of blankð Þ
100=Absorbance of control:
The VCEAC for ABTS assay and the IC50 value were
calculated as half the concentration of the sample that
can scavenge 50% of the DPPH free radical.
Spheroid assay
Seven hundred and fifty HCT-116 cells were seeded in an
ultra-low attachment round bottom 96-well plate (Coster,
Kennebunk, ME, USA), and cultured for 4 days. After
spheroids were formed, half of the media was replaced
with complete media containing 2 times the required dos-
age of nootkatone, and spheroids were incubated for 3
days. Spheroid viability was measured by the CellTiter-
Glo® 3D Cell Viability Assay (Promega, Madison, WI,
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USA) in accordance with the manufacturer’s instuctions.
Spheroid volume was calculated using the following for-
mula: 0.5 × Length × Width2.
Statistics
Data are expressed as mean ± SD from at least three
independent experiments. Statistical analyses were
performed using one-way ANOVA test. All compari-
sons are relative to untreated or carrier controls
and significant differences have been indicated as
*p < 0.05; **p < 0.01; ***p < 0.001.
Results
Effects of A. oxyphylla extract on cell growth
A. oxyphylla has been used as a traditional Chinese
medicine for many years. However, the molecular mech-
anism of A. oxyphylla extract as an anticancer agent has
not been elucidated. In the current study, ethanol ex-
tracts of A. oxyphylla have been obtained and examined
for potential antiproliferative activity in two human colo-
rectal cancer cell lines. Treatment with A. oxyphylla ex-
tract affected HCT-116 and SW480 cell growth in a
dose- and time-dependent manner with IC50 values of
89.3 μg/ml and > 100 μg/ml, respectively. (Fig. 1a–b). At
48 h and 96 h, A. oxyphylla significantly inhibited cell
growth both in p53 wild type (HCT-116) and p53 mu-
tant colorectal cancer cells (SW480), at a concentration
of 100 μg/ml.
Antioxidant activity of A. oxyphylla extracts
Antioxidant activity of natural compounds has been
shown to be highly related to anticancer effects [23].
Thus, the antioxidant activity of A. oxyphylla extract has
been investigated. DPPH and ABTS radical scavenging
activity assays were performed to determine the antioxi-
dant capacity of A. oxyphylla extract at various concen-
trations. The effects of A. oxyphylla extract and ascorbic
acid on the ABTS radical compound are shown in
Fig. 2a. The ABTS scavenging activities increased in cor-
relation with increasing concentrations of A. oxyphylla
extract. As a positive control, L-ascorbic acid displayed
high antioxidant activity with decreased ABTS radical at
a low concentration. Similarly, the DPPH radical scaven-
ging activity of A. oxyphylla extract is presented in Fig.
2b. Scavenging activity increased in a dose-dependent
manner up to 1000 ng/mL; with a similar trend observed
in the ABTS assay. Antioxidant activity was also mea-
sured using a luciferase construct containing the antioxi-
dant response element (ARE). After transfection into
HCT-116 cells, luciferase activity was increased in the
presence of A. oxyphylla, suggesting that A. oxyphylla
may activate NRF2 which binds ARE sites (Fig. 2c). In
addition, Heme oxygenase-1 (HO-1) protein levels were
analyzed by western blot as a marker for antioxidant ac-
tivity to confirm the antioxidant effect of the extract. Re-
sults showed that HO-1 protein levels increased in a
dose-dependent manner (Fig. 2d). Overall, our results in-
dicate that A. oxyphylla possesses antioxidant activity.
NAG-1 and cyclin D1 expression in the presence of A.
oxyphylla
To elucidate the molecular mechanism by which A. oxy-
phylla affects anticancer activity in colorectal cancer
cells, expression of NAG-1 and cyclin D1 have been de-
termined. An increase in NAG-1 expression was ob-
served, whereas cyclin D1 expression level was decreased
Fig. 1 Proliferation assay of colorectal cancer cells in the presence of A. oxyphylla. a HCT-116 and b SW480 cells were treated with various
concentrations of A. oxyphyllal at different time points. Cell numbers were measured by the Cell Proliferation Assay (Promega) after adding an
indicated dose of A. oxyphylla. DMSO was used as a control. The results from five independent experiments are shown as mean ± SD with
statistical significance displayed as *p < 0.05, ***p < 0.001, compared to DMSO-treated cells
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in all four colorectal cancer cell lines treated with A.
oxyphylla (Fig. 3a–d). These results suggest that A. oxy-
phylla extract may regulate colorectal cancer cell growth
by elevating NAG-1 protein expression and decreasing
cyclin D1 protein expression.
Nootkatone exhibits anti-tumorigenic activity in
colorectal cancer cells
One of the bioactive compounds found in A. oxy-
phylla is nootkatone. (Fig. 4a) [6]. To determine
whether nootkatone can account for the antiprolifera-
tive effect of A. oxyphylla, we analyzed cell growth
both by counting cells and by performing colony and
spheroid formation assays. Colorectal cancer cells
were treated with nootkatone at concentrations of
10 μM, 50 μM and 100 μM, wherein nootkatone treat-
ment resulted in cell growth inhibition in a dose and
time dependent manner (Fig. 4b), similar to the trend
observed following A. oxyphylla extract treatment
(Fig. 1). Furthermore, in the colony formation assay,
nootkatone showed a dose-dependent inhibition of
colony formation in two colorectal cancer cell lines
(Fig. 4c). In the spheroid formation assay, nootkatone
decreased spheroid formation (viability and volume)
in HCT-116 cells (Fig. 4d), indicating that nootkatone
possesses anti-tumorigenic activity not only in a 2D
culture system, but also in a 3D culture system.
Nootkatone decreases cyclin D1 and increases NAG-1
expression
We examined whether nootkatone may decrease cyc-
lin D1 or increase NAG-1 expression at the transcrip-
tion level. An increased RNA level of NAG-1 was
observed in the presence of nootkatone treatment,
whereas cyclin D1 RNA levels did not change in cells
treated with nootkatone (Fig. 5a). Protein levels of
NAG-1 and cyclin D1 were also analyzed revealing
that both NAG-1 and cyclin D1 were altered by noot-
katone treatment at the protein level (Fig. 5b). Taken
together, our results indicate that nootkatone may
affect cyclin D1 at the protein level and NAG-1 at
the transcriptional level.
Fig. 2 Antioxidant activity of A. oxyphylla. a 2,2-Azino-bis3-ethylbenthiazoline-6-sulfonic acid (ABTS) radical scavenging ability of the ethanol
fraction of A. oxyphylla. Vitamin C (L-ascorbic acid) was used as a positive control. Quantification of the result from three independent
experiments (n = 3) is shown as mean ± SD. b The DPPH radical scavenging activities of the ethanol fraction of A. oxyphyllal. Quantification of the
results from three independent experiments (n = 3) is shown as mean ± SD. c HCT-116 cells were co-transfected with pARE (Antioxidant response
element)-Luc and pRL-null, and luciferase activity was measured. The y-axis shows the number of fold induction of RLU (firefly luciferase activity/
Renilla luciferase activity), compared with control of RLU. Quantification of the result from three independent transfections (n = 3) is shown as
mean ± SD with statistical significance as *p < 0.05, ***p < 0.001. d Western blot analysis was conducted to measure HO-1 (Heme oxygenase-1)
levels. HCT-116 cell was treated with A. oxyphylla extract at various doses for 24 h. β-actin was measured as a loading control for the samples
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Nootkatone decreases cyclin D1 expression via
proteosomal pathway
To clarify the molecular mechanism by which nootka-
tone decreases cyclin D1 protein levels, a protein sta-
bility assay was performed wherein HCT-116 and
SW480 cell lines were treated with puromycin and
proteosomal inhibitors. In both cell lines, cyclin D1
protein expression was dramatically decreased by
nootkatone treatment compared to the control, indi-
cating that nootkatone may affect the stability of the
cyclin D1 protein in the cells (Fig. 6a). Furthermore,
proteosomal inhibitors epoxomicin and MG132 were
combined with nootkatone to determine whether this
would rescue the protein-destabilizing effect of cyclin
D1 by nootkatone. Results showed that epoxomicin
and MG132 partially restored cyclin D1 protein levels,
indicating that nootkatone may affect cyclin D1
degradation through a proteosomal degradation
pathway-related mechanism (Fig. 6b).
Nootkatone increases transcriptional expression of NAG-1
via EGR-1
To examine the direct effect of nootkatone on NAG-1
expression, a NAG-1 promoter-luciferase construct con-
taining 1086 bp was transfected into HCT-116 cells and
luciferase activity was measured following nootkatone
treatment. NAG-1 promoter activity was increased in a
dose-dependent manner, with the highest expression
corresponding to nootkatone treatment at a concentra-
tion of 100 μM (Fig. 7a). To identify the response elem-
ent region in the NAG-1 promoter which responded to
nootkatone, three deletion mutant clone plasmids were
designed and analyzed for nootkatone-inducing activity
following transfection. The response element position
Fig. 3 Western blot analysis of NAG-1 and cyclin D1 following A. oxyphylla treatment in colorectal cancer cells. a HCT-116, b SW480, c DLD-1, and
d HT-29 cells were treated with A. oxyphylla at various concentrations for 24 h in serum-free media. Each cell lysate was subjected to western blot
analysis wherein cyclin D1, NAG-1, and β-actin expression were measured. The bar graphs represent the relative protein expression levels of NAG-
1 or cyclin D1 after normalization to β-actin
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which was the most affected by nootkatone seems to be
located within the 133 bp of the NAG-1 promoter (Fig.
6b). It is known that EGR-1 plays a role in transcrip-
tional regulation of NAG-1 in this promoter region [19].
To confirm whether EGR-1 plays a role in nootkatone-
induced NAG-1 expression, an EGR-1 luciferase vector
was co-transfected with the 133 bp NAG-1 luciferase
construct. The results indicated that EGR-1 indeed in-
creased luciferase activity and activated the 133 bp re-
gion of the NAG-1 promoter (Fig. 7c). Subsequently, we
measured whether EGR-1 protein was increased by the
nootkatone treatment. Nootkatone led to increased
EGR-1 expression in both HCT-116 and SW480 cells in
a dose-dependent manner (Fig. 7d). Finally, we deter-
mined whether nootkatone affects EGR-1 expression at
the transcriptional level. The result showed EGR-1 pro-
moter activity was increased in the presence of nootka-
tone in a dose-dependent manner (Fig. 7e), indicating
that nootkatone induces EGR-1 at the transcriptional
level ultimately leading to the induction of NAG-1 pro-
moter activity.
Discussion
Plant extracts and its bioactive compounds have been
studied in cancer research. Recent data also suggested
the usage of plant derived compounds in new
Fig. 4 Nootkatone exhibits anticancer activity in colorectal cancer cells. a The structure of nootkatone. b Cell proliferation assay. HCT-116 and
SW480 colorectal cancer cells were treated with various concentrations of nootkatone and cells were counted using hemocytometer. The y-axis
shows the cell number and x axis shows the time. Ethanol (EtOH) was used as the vehicle for nootkatone. Quantification of the result from three
independent experiments (n = 3) is shown as mean ± SD with statistical significance displayed as *p < 0.05, **p < 0.01, and ***p < 0.001. c Colony
formation assay. HCT-116 and SW480 cells were grown in media containing nootkatone for 9 days. Number of colonies were counted and
presented in the bottom graph. The results from three independent experiments (n = 3) is shown as mean ± SD with statistical significance
displayed as *p < 0.05, **p < 0.01, and ***p < 0.001 compared to EtOH-treated cells. N.S., not significant. d Spheroid viability assay. HCT-116 tumor
spheroids were treated with nootkatone. Phase-contrast images showed that the size of the spheroid, especially the proliferating zone shrinks in
a dose-dependent manner. Scale bars represent 500 μm. left graph, spheroid viability was measured by CellTiter-Glo® 3D Cell Viability Assay
(Promega). right graph, spheroid volume was calculated as described in the Method section. The graph represents three independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001
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generation immunotherapeutic vaccine [24]. A. oxy-
phylla possesses a wide range of biological activities,
including anti-diabetes, anti-liver fibrosis, antidiar-
rheal, and neuronal protection effects [1]. Moreover,
several publications have reported anticancer effects
of A. oxyphylla such as in liver cancer cells via AKT
pathway suppression [5]. Our findings further confirm
its anti-proliferative activity in colorectal cancer cells.
Nootkatone is one of nine bioactive compounds
found in A. oxyphylla [6], and showed ability to in-
hibit the expression of inducible nitric oxide synthase
(iNOS) and reduce NO production in lipopolysacchar-
ide (LPS) stimulated RAW264.7 cells [25]. Addition-
ally, nootkatone increased survival rates in septic
mice by increasing HO-1 expression [25]. Although
nootkatone has been linked to anticancer activity in
lung cancer via the AMPK pathway [8], the effects of
nootkatone against colorectal cancer and its mecha-
nisms underlying these effects remain unknown.
Metastatic cancer encompasses a diverse collection
of cells that possess different genetic characteristics
and are controlled by many proteins [26–28]. It is
also suggested that autophagy plays a role in metas-
tasis [29]. Nootkatone inhibits protein expression
that are involved in metastatic cancer and induces
autophagy [30]. Thus, molecular elucidation of noot-
katone in anti-tumorignesis may lead to better
understanding of cancer treatment in metastatic can-
cer treatment.
In this report, we show that nootkatone treatment
contributes to inhibition of cell proliferation in colorec-
tal cancer cells. Our results also suggest that cyclin D1
suppression and NAG-1 induction may at least in part
be mechanistically involved in nootkatone-induced anti-
tumorigenic activity.
The suppression of cyclin D1 and induction of
NAG-1 by nootkatone were observed at a concentra-
tion of 100 μM. A similar result was reported in lung
cancer cells where 100 μM of nootkatone was re-
quired to obtain cell growth inhibition [8]. Since the
systemic concentration of nootkatone and its concen-
tration in tissues has not been reported, and most
phytochemicals could reach even higher concentra-
tions in the gastrointestinal (GI) track, the speculation
that nootkatone probably reaches 100 μM in the GI
track is reasonable. Therefore, the large intestinal epi-
thelia, including colon and rectum, could be
highlighted as a logical target tissue to further explore
nootkatone as an anti-cancer treatment. Additionally,
since nootkatone is bio-transformed to various metab-
olites by fungal strains, the impact of specific nootka-
tone metabolites may be of particular interest in
future cancer studies [31]. In this regard, nootkatone
metabolites should be considered as an important
Fig. 5 Nootkatone increases NAG-1 and decreases cyclin D1 expression. a Total RNA was isolated for RT-PCR analysis from nootkatone-treated
HCT-116 and SW480 cells. GAPDH was used as housekeeping control gene. NAG-1 RNA levels increased in a dose-dependent manner, whereas
expression level of cyclin D1 did not change. b Total proteins were isolated from nootkatone-treated HCT-116 and SW480 cells for western blot
analysis. Nooktatone treatment up-regulated NAG-1 protein, while cyclin D1 expression decreased in a dose-dependent manner. β-actin antibody
was used as loading control. The relative expression was determined by the Image J program and represented them in the bottom
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compound with respect to cancer progression. A
number of reports suggest that cyclin D1 could be a
target for many phytochemicals since cyclin D1
downregulation is common in various phytochemical-
treated samples [32, 33]. Most phytochemicals affect
cyclin D1 at the protein level, as was confirmed in
the current study regarding nootkatone’s effects on
cyclin D1 protein. Similarly, DIM, EGCG, damna-
canthal, and 6-ginerol downregulates cyclin D1 post-
translationaly, thereby accounting for the anti-
tumorigenic activity of these compounds [16, 32–34].
Cyclin D1 controls many pathways in addition to the
cell cycle [35], suggesting that the benefits of cyclin
D1 inhibition in cancer may result from several
mechanisms.
Transcriptional regulation of NAG-1 is modulated by
several cis- and trans-acting elements [12]. The 133 bp
promoter region of NAG-1 contains several transcrip-
tional binding sites, including C/EBPβ [36], p53 [37],
EGR-1 [19], and Sp1 [12]. These transcription factors are
responsible for the downstream effects of several
anticancer compounds including COX inhibitors, PPARγ
ligands and cancer chemo-preventive agents [38] which
increase NAG-1 transcription. Interestingly, sulindac sul-
fide (or troglitazone)-mediated NAG-1 up-regulation is
dependent on the transcription factor EGR-1 in colon
cancer cells [39]. EGR-1 binding sites have been detected
in the NAG-1 promoter, overlapping the Sp1 binding site.
Here, we report that nootkatone increases EGR-1 both at
the protein level as well as at the transcriptional level in
colorectal cancer cells, and facilitates NAG-1 promoter ac-
tivity. This suggests that EGR-1 may be responsible for
nootkatone -mediated NAG-1 up-regulation. Since
PPARγ ligand troglitazone also increases EGR-1 expres-
sion, we examined whether nootkatone may affect PPARγ
transcriptional factors. As expected, nootkatone treatment
increased PPARγ binding activity as assessed using a re-
porter construct bearing the PPAR response element (data
not shown). Nonetheless, PPARγ activation may not be in-
volved in nootkatone-induced NAG-1 expression at the
transcriptional level. Since the emerging pieces of evidence
indicate that repurposing of drugs is crucial to the faster
Fig. 6 Nootkatone controls cyclin D1 at the protein level. a HCT-116 and SW480 cells were pre-treated with 100 μM of nootkatone for 1 h and
exposed to 20 μg/ml of puromycin (Puro) at different time points. The cell lysate was harvested at each time point, wherein cyclin D1 and β actin
protein levels were detected. Quantitative analysis was performed by Image J. The bottom graph represents degradation of the cyclin D1 protein
over time. β-actin was used as loading control. b HCT-116 and SW480 cells were pre-treated with DMSO, 10 μM of MG132, or 0.1 μM of
epoxomicin, followed by treatment with 50 μM (HCT-116) or 100 μM (SW480) nootkatone for 24 h. β-actin was used as loading control.
Quantitative analysis was performed by Image J
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and cheaper discovery of anti-cancerous drugs [40], noot-
katone should be seriously considered for the design of fu-
ture cancer drugs.
Conclusions
Our results indicate that A. oxyphylla and its bioactive
compound nootkatone exhibit antiproliferative activity
in colorectal cancer cells. NAG-1 induction and cyclin
D1 downregulation may contribute at least in part to the
antiproliferative activity of nootkatone.
Abbreviations
NAG-1: Nonsteroidal anti-inflammatory drug activated gene-1;
GDF15: Growth differentiation factor 15; EGR-1: Early Growth Response 1;
PTEN: Phosphatase and tensin homolog; PPARγ: Peroxisome proliferator-
activated receptor gamma; ABTS: 2,2′-Azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid); DPPH: 2,2-diphenyl-1-picrylhydrazyl; C/EBPβ: CCAAT/enhancer-
binding protein beta; DIM: 3–3′-di-indolymethane; EGCG: Epigallocatechin
gallate; Sp1: Specificity protein 1; COX: Cyclooxygenase; HO-1: Heme
Oxygenase-1
Acknowledgements
We thank Hyunjin Moon and Yukyung Hong from Department of Veterinary
Medicine, College of Veterinary Medicine, Seoul National University for their
technical supports.
Authors’ contributions
EY and SJB designed the study. EY, JL, PL, CK, and EP performed the
experiments. EY, JL, PL, JR, and SJB analyzed, interpreted the data and wrote
the article. All authors have approved this submission.
Funding
This work was supported by the Research Institute for Veterinary Science,
and BK21 PLUS Program for Creative Veterinary Science Research Center,
Seoul National University, and by a National Research Foundation of Korea
(NRF) grant funded by the Korean government (2018R1A2B2002923) to S.J.B.
This work was also partially supported by a clinical research grant (NCC-
1810150) provided by the National Cancer Center to J.R. and S.J.B. The
Fig. 7 Nootkatone controls the NAG-1 expression at the transcriptional level. a Nootkatone increases NAG-1 promoter activity. HCT-116 cells were
transfected with pNAG-1 − 1086/+ 41 luciferase and pRL-null plasmid. The cells were treated with EtOH or various concentrations of nootkatone
for 24 h, and luciferase activity was measured. The y-axis refers to the ratio of firefly luciferase over renillar luciferase activity. The EtOH-treated
cells were set as 1.0. Statistical significance was displayed as *p < 0.05, ***p < 0.001 versus EtOH-treated cells. The data represent mean ± SD from
three independent experiments. b Three deletion NAG-1 promoter constructs were co-transfected with pRL-null vector into HCT-116 cells. The
cells were treated with EtOH or 100 μM of nootkatone for 24 h, and luciferase activity was measured. Fold induction refers to the ratio of
luciferase activity in nootkatone-treated cells versus EtOH-treated cells. Statistical significance was displayed as **p < 0.01 and ***p < 0.001 versus
EtOH-treated cells. The data represent mean ± SD from three independent experiments. c HCT-116 cells were co-transfected with wild type
pNAG-1 − 133/+ 41 in the presence of empty or EGR-1 expression vector. Cells were subsequently treated with 100 μM nootkatone for 24 h. The
results are presented as means ± S.D. of three independent transfections. d Western blot of EGR-1 protein in the presence of nootkatone. β-actin
was used as loading control. e Luciferase activity of EGR-1 promoter-luciferase construct (pEGR-1260-LUC). The cells were treated with EtOH or
nootkatone for 24 h prior to measurement of luciferase activity. Fold induction refers to the ratio of luciferase activity in nootkatone-treated cells
compared to EtOH-treated cells. Statistical significance represented as *p < 0.05, ***p < 0.001 versus EtOH-treated cells. n.s. represents not
significant. The data represent mean ± SD from four independent experiments
Yoo et al. BMC Cancer          (2020) 20:881 Page 10 of 12
funding agency did not have any influence in the design of the study and
collection, analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
The materials during the current study are available from the corresponding
author on reasonable request.





The authors declare that there is no conflict of interest.
Author details
1Department of Veterinary Medicine, College of Veterinary Medicine and
Research Institute for Veterinary Science, Seoul National University, Seoul
08826, South Korea. 2Department of Otolaryngology-Head and Neck Surgery,
Research Institute and Hospital, National Cancer Center, Goyang, South
Korea. 3R&D Center, EastHill Co. 33, Omokcheon-ro 132 beon-gil,
Gwonseon-gu, Suwon-si, Gyeonggi-do 16642, South Korea.
Received: 2 July 2020 Accepted: 3 September 2020
References
1. Zhang Q, Zheng Y, Hu X, Hu X, Lv W, Lv D, Chen J, Wu M, Song Q, Shentu
J. Ethnopharmacological uses, phytochemistry, biological activities, and
therapeutic applications of Alpinia oxyphylla Miquel: a review. J
Ethnopharmacol. 2018;224:149–68.
2. Xie Y, Xiao M, Li D, Liu H, Yun F, Wei Y, Sang S, Du G. Anti-diabetic effect of
Alpinia oxyphylla extract on 57BL/KsJ db−/db- mice. Exp Ther Med. 2017;
13(4):1321–8.
3. Balta C, Ciceu A, Herman H, Rosu M, Boldura O-M, Hermenean A. Dose-
dependent Antifibrotic effect of Chrysin on regression of liver fibrosis: the
role in extracellular matrix remodeling. Dose-Response. 2018;16:
155932581878983.
4. Wang S, Zhao Y, Zhang J, Huang X, Wang Y, Xu X, Zheng B, Zhou X, Tian H,
Mei Q. Antidiarrheal effect of Alpinia oxyphylla Miq. (Zingiberaceae) in
experimental mice and its possible mechanism of action. J Ethnopharmacol.
2015;168:182–90.
5. Hui F, Qin X, Zhang Q, Li R, Liu M, Tianshu R, Zhao M, Zhao Q. Alpinia
oxyphylla oil induces apoptosis of hepatocellular carcinoma cells via PI3K/
Akt pathway in vitro and in vivo. Biomed Pharmacother. 2019;109:2365–74.
6. Li Y-H, Chen F, Wang J-F, Wang Y, Zhang J-Q, Guo T. Analysis of nine
compounds from Alpinia oxyphylla fruit at different harvest time using
UFLC-MS/MS and an extraction method optimized by orthogonal design.
Chem Cent J. 2013;7:134.
7. Choi H-J, Lee J-H, Jung Y-S. (+)-Nootkatone inhibits tumor necrosis factor α/
interferon γ-induced production of chemokines in HaCaT cells. Biochem
Biophys Res Commun. 2014;447(2):278–84.
8. Hung LVM, Moon JY, Ryu J-y, Cho SK. Nootkatone, an AMPK activator
derived from grapefruit, inhibits KRAS downstream pathway and sensitizes
non-small-cell lung cancer A549 cells to adriamycin. Phytomedicine. 2019;
63:153000.
9. Qi Y, Cheng X, Jing H, Yan T, Xiao F, Wu B, Bi K, Jia Y. Combination of
schisandrin and nootkatone exerts neuroprotective effect in Alzheimer’s
disease mice model. Metab Brain Dis. 2019;34(6):1689–703.
10. Lin RJ, Yen CM, Chou TH, Chiang FY, Wang GH, Tseng YP, Wang L, Huang
TW, Wang HC, Chan LP, et al. Antioxidant, anti-adipocyte differentiation,
antitumor activity and anthelmintic activities against Anisakis simplex and
Hymenolepis nana of yakuchinone a from Alpinia oxyphylla. BMC
Complement Altern Med. 2013;13:237.
11. Chun KS, Park KK, Lee J, Kang M, Surh YJ. Inhibition of mouse skin tumor
promotion by anti-inflammatory diarylheptanoids derived from Alpinia
oxyphylla Miquel (Zingiberaceae). Oncol Res. 2002;13(1):37–45.
12. Baek SJ, Horowitz JM, Eling TE. Molecular cloning and characterization
of human nonsteroidal anti-inflammatory drug-activated gene promoter.
Basal transcription is mediated by Sp1 and Sp3. J Biol Chem. 2001;
276(36):33384–92.
13. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase
inhibitors regulate the expression of a TGF-beta superfamily member
that has proapoptotic and antitumorigenic activities. Mol Pharmacol.
2001;59(4):901–8.
14. Baek SJ, Okazaki R, Lee SH, Martinez J, Kim JS, Yamaguchi K, Mishina Y,
Martin DW, Shoieb A, McEntee MF, et al. Nonsteroidal anti-inflammatory
drug-activated gene-1 over expression in transgenic mice suppresses
intestinal neoplasia. Gastroenterology. 2006;131(5):1553–60.
15. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon
A, Goswami T, Wang YE, Clark AB, et al. A function for cyclin D1 in DNA
repair uncovered by protein interactome analyses in human cancers.
Nature. 2011;474(7350):230–4.
16. Lee SH, Cekanova M, Baek SJ. Multiple mechanisms are involved in 6-
gingerol-induced cell growth arrest and apoptosis in human colorectal
cancer cells. Mol Carcinog. 2008;47(3):197–208.
17. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM. Early
growth response-1-dependent apoptosis is mediated by p53. J Biol Chem.
1997;272(32):20131–8.
18. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I.
The Egr-1 transcription factor directly activates PTEN during irradiation-
induced signalling. Nat Cell Biol. 2001;3(12):1124–8.
19. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase
inhibitors induce the expression of the tumor suppressor gene EGR-1,
which results in the up-regulation of NAG-1, an antitumorigenic protein.
Mol Pharmacol. 2005;67(2):356–64.
20. Wilmanski T, Zhou X, Zheng W, Shinde A, Donkin SS, Wendt M, Burgess JR,
Teegarden D. Inhibition of pyruvate carboxylase by 1α,25-dihydroxyvitamin
D promotes oxidative stress in early breast cancer progression. Cancer Lett.
2017;411:171–81.
21. Lee J, Kim I, Yoo E, Baek SJ. Competitive inhibition by NAG-1/GDF-15 NLS
peptide enhances its anti-cancer activity. Biochem Biophys Res Commun.
2019;519(1):29–34.
22. Prasansuklab A, Tencomnao T. Acanthus ebracteatus leaf extract provides
neuronal cell protection against oxidative stress injury induced by
glutamate. BMC Complem Altern Med. 2018;18(1):278.
23. Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in
tumorigenesis. Cell Mol Life Sci. 2020. https://doi.org/10.1007/s00018-020-03536-5.
24. Gupta B, Sadaria D, Warrier VU, Kirtonia A, Kant R, Awasthi A, Baligar P,
Pal JK, Yuba E, Sethi G, et al. Plant lectins and their usage in preparing
targeted nanovaccines for cancer immunotherapy. Semin Cancer Biol.
2020. In Press.
25. Tsoyi K, Jang HJ, Lee YS, Kim YM, Kim HJ, Seo HG, Lee JH, Kwak JH, Lee D-U,
Chang KC. (+)-Nootkatone and (+)-valencene from rhizomes of Cyperus
rotundus increase survival rates in septic mice due to heme oxygenase-1
induction. J Ethnopharmacol. 2011;137(3):1311–7.
26. Shinde A, Paez JS, Libring S, Hopkins K, Solorio L, Wendt MK.
Transglutaminase-2 facilitates extracellular vesicle-mediated establishment
of the metastatic niche. Oncogenesis. 2020;9(2):16.
27. Libring S, Shinde A, Chanda MK, Nuru M, George H, Saleh AM, Abdullah A,
Kinzer-Ursem TL, Calve S, Wendt MK, et al. The dynamic relationship of
breast Cancer cells and fibroblasts in Fibronectin accumulation at primary
and metastatic tumor sites. Cancers. 2020;12(5):1270.
28. Shinde A, Libring S, Alpsoy A, Abdullah A, Schaber JA, Solorio L, Wendt MK.
Autocrine Fibronectin inhibits breast Cancer metastasis. Mol Cancer Res.
2018;16(10):1579–89.
29. Shinde A, Hardy SD, Kim D, Akhand SS, Jolly MK, Wang W-H, Anderson JC,
Khodadadi RB, Brown WS, George JT, et al. Spleen tyrosine kinase–mediated
autophagy is required for epithelial–Mesenchymal plasticity and metastasis
in breast Cancer. Cancer Res. 2019;79(8):1831–43.
30. Zhu X, Li X, Chen Z. Inhibition of anticancer growth in retinoblastoma cells
by naturally occurring sesquiterpene nootkatone is mediated via autophagy,
endogenous ROS production, cell cycle arrest and inhibition of NF-κB
signalling pathway. J BUON. 2020;25(1):427–31.
31. Gliszczyńska A, Łysek A, Janeczko T, Świtalska M, Wietrzyk J, Wawrzeńczyk C.
Microbial transformation of (+)-nootkatone and the antiproliferative activity
of its metabolites. Bioorg Med Chem. 2011;19(7):2464–9.
32. Zhang X, Sukamporn P, Zhang S, Min KW, Baek SJ. 3,3′-diindolylmethane
downregulates cyclin D1 through triggering endoplasmic reticulum stress in
colorectal cancer cells. Oncol Rep. 2017;38(1):569–74.
Yoo et al. BMC Cancer          (2020) 20:881 Page 11 of 12
33. Sukamporn P, Rojanapanthu P, Silva G, Zhang X, Gritsanapan W, Baek SJ.
Damnacanthal and its nanoformulation exhibit anti-cancer activity via cyclin
D1 down-regulation. Life Sci. 2016;152:60–6.
34. Zhang X, Min K-W, Wimalasena J, Baek SJ. Cyclin D1 degradation and p21
induction contribute to growth inhibition of colorectal cancer cells induced
by epigallocatechin-3-gallate. J Cancer Res Clin Oncol. 2012;138(12):2051–60.
35. Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer
treatment. Int J Mol Med. 2016;94(12):1313–26.
36. Nualsanit T, Rojanapanthu P, Gritsanapan W, Lee SH, Lawson D, Baek SJ.
Damnacanthal, a noni component, exhibits antitumorigenic activity in
human colorectal cancer cells. J Nutr Biochem. 2012;23(8):915–23.
37. Wilson LC, Baek SJ, Call A, Eling TE. Nonsteroidal anti-inflammatory drug-
activated gene (NAG-1) is induced by genistein through the expression of
p53 in colorectal cancer cells. Int J Cancer. 2003;105(6):747–53.
38. Baek SJ, Eling T. Growth differentiation factor 15 (GDF15): a survival
protein with therapeutic potential in metabolic diseases. Pharmacol
Ther. 2019;198:46–58.
39. Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-
activated receptor gamma (PPAR gamma ) ligand, selectively induces the early
growth response-1 gene independently of PPAR gamma. A novel mechanism
for its anti-tumorigenic activity. J Biol Chem. 2003;278(8):5845–53.
40. Kirtonia A, Gala K, Fernandes SG, Pandya G, Pandey AK, Sethi G, Khattar E,
Garg M. Repurposing of drugs: an attractive pharmacological strategy for
cancer therapeutics. Semin Cancer Biol. 2020;S1044-579X(20):30094–8.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Yoo et al. BMC Cancer          (2020) 20:881 Page 12 of 12
